Cerus Corp
NASDAQ:CERS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.52
2.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cerus Corp
Cerus Corp
Capital Expenditures
Cerus Corp
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cerus Corp
NASDAQ:CERS
|
Capital Expenditures
-$1.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
27%
|
CAGR 10-Years
2%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Capital Expenditures
-$53.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Capital Expenditures
-$95.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Capital Expenditures
-$117.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-19%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Capital Expenditures
-$120.7m
|
CAGR 3-Years
-120%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-34%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Capital Expenditures
-$43.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
Cerus Corp
Glance View
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
See Also
What is Cerus Corp's Capital Expenditures?
Capital Expenditures
-1.9m
USD
Based on the financial report for Sep 30, 2024, Cerus Corp's Capital Expenditures amounts to -1.9m USD.
What is Cerus Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
2%
Over the last year, the Capital Expenditures growth was 68%. The average annual Capital Expenditures growth rates for Cerus Corp have been -26% over the past three years , 27% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
